

Financial Tearsheet

Company Overview

Neuropathix, Inc. is a biopharmaceutical medchem company focused on the research and development of a pipeline of patented socially responsible pain management therapeutics to treat patients with significant unmet medical needs. The Company's family of proprietary molecules focuses on treating oxidative stress-related diseases, chronic pain management and neurodegenerative disorders. The therapeutic targets include chemotherapy-induced peripheral neuropathy (CIPN), a chronic neuropathy caused by toxic chemotherapeutic agents; hepatic encephalopathy (HE), a neurotoxic brain-liver disorder caused by excessive concentrations of ammonia and ethanol in the brain; mild traumatic brain injury (mTBI), a disorder associated with single and repetitive impact injuries; and chronic traumatic encephalopathy (CTE) a disease associated with highly repetitive impact injuries in professional and amateur sports. Neuropathix conducts its research and development efforts at the Pennsylvania Biotechnology Center of Bucks County in Doylestown, PA.

Recent Financial News

Date	Headline
Aug 24, 2021	Neuropathix, Inc. Forms Dermique Incorporated its New Wholly Owned Subsidiary for the Ownership and Commercialization of the Company's Over-The-Counter Cosmeceutical Assets
Aug 12, 2021	Neuropathix, Inc. Appoints Michael Ropacki, PhD to the Company's Scientific Advisory Board
Jul 20, 2021	Neuropathix, Inc. Announces Publication of PCT Patent Application for the Treatment of Radiation Dermatitis and Other Skin Disorders
May 06, 2021	Neuropathix, Inc. Announces Publication of Validated Preclinical Studies on KLS-13019 in the British Journal of Pharmacology
Jan 25, 2021	Neuropathix, Inc. CEO Recaps 2020 Advances and Potential Ahead











IR Contacts

Investor Relations Investor Relations Firm CORE IR 377 Oak Street Garden City, NY 11530 (516) 222-2285 www.coreir.com Contact: John Marco Johnm@coreir.com	Transfer Agent Securities Transfer Corp. 2901 Dallas Parkway, Suite 380, Plano, TX 75093 (469) 633-0101 www.stctransfer.com
Auditors DBB McKennon 12790 El Camino Real #130 San Diego, CA 92130 (858) 217-4035 www.dbbmckennon.com	Corporate Counsel Procopio, Cory, Hargreaves & Savitch LLP. 525 B Street, Suite 2200 San Diego, CA 92101 (619) 238-1900 www.procopio.com

Stock Performance

Stock Fundamentals	Value
Today's Open	0.0524
Volume	5,304
Day Range	0.0427 - 0.0524
52 Week Range	0.0381 - 0.9195
Bid/Ask	0.0000 / 0.0000
Bid/Ask Size	0 X 0
Previous Close	0.0488
Market Cap	3.76 million
Shares Outstanding	87.98 million
Dividend/Yield	0.0000 / 0.0000%
EPS (TTM)	-0.053500
P/E Ratio (TTM)	N/A

Recent XBRL Filings

Filing Date ▾	Form Type	Description	View
Aug 06, 2021	10-Q	Quarterly report	 
May 13, 2021	10-Q	Quarterly report	 
Mar 30, 2021	10-K	Annual report	 
Nov 12, 2020	10-Q	Quarterly report	 
Aug 12, 2020	10-Q	Quarterly report	 

Management Team

Dean Petkanas, Chairman & CEO

William A. Kinney, PHD, Chief Scientific Officer

Thoma Kikis, Chief Communications Officer, Board Director

Mark Corrao, Chief Financial Officer

Board of Directors

Dean Petkanas, Chairman & CEO

Thoma Kikis, Founder / Chief Communications Officer, Board Director

Robert Malasek, Director

Blake Schroeder, Director

Timothy Scott, PhD, Director